Relapsed or Refractory Multiple Myeloma Clinical Trials
5 recruiting trials for Relapsed or Refractory Multiple Myeloma. Eligibility criteria explained in plain English.
TrialFinderData lists 5 Relapsed or Refractory Multiple Myeloma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 60% (3 studies); the largest phase groups are Phase 1: 3, Phase 3: 1, Phase 1 / Phase 2: 1.
Research is led by Jiangsu Simcere Pharmaceutical Co., Ltd. (1), Celgene (1), Excyte Biopharma Ltd (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is SIM0500 (drug, 1 trial), followed by mezigdomide, Pomalidomide.
Track Relapsed or Refractory Multiple Myeloma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or...
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and...
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone...
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight...
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in...
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for...
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a...
Explore Other Conditions
Frequently Asked Questions
There are currently 5 clinical trials for Relapsed or Refractory Multiple Myeloma, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Relapsed or Refractory Multiple Myeloma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Relapsed or Refractory Multiple Myeloma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.